1 Introduction
==============

The number of genome-wide association studies (GWAS) is growing. Consortia are unravelling associations between genetic variants and traits with ever increasing sample sizes. Available GWAS cover many areas of medicine, behaviour and biology. In addition, initiatives such as the Genotype-Tissue Expression (GTEx) project ([@bty982-B3]) investigate the tissue-dependent variation in gene expression levels and identify associations with expression quantitative trait loci (eQTLs), and methods such as S-PrediXcan ([@bty982-B1]) allow prediction of tissue-specific expression levels using GWAS summary statistics. These advances can help map GWAS associations to protein targets in a tissue-specific manner. [@bty982-B5] have shown that bipartite drug--target networks can be useful to assess polypharmacology (drugs binding several targets) or polyspecificity (targets interacting with dissimilar drugs), by providing a simple bipartite representation of drug--target interactions. In this paper, we present Drug Targetor (drugtargetor.com), a web interface that allows users to browse over 500 GWAS to identify drugs and targets of interest using bipartite drug--gene networks. These networks are phenotype-dependent: drugs and genes are ordered using GWAS-derived genetic scores. Drug Targetor uses several data layers: drug--target interactions (how a drug binds a target), drug--gene interactions (how a drug influences gene expression), genetic scores to order drugs and genes by association with a phenotype and predicted gene expression levels derived from GWAS and eQTLs.

2 Materials and methods
=======================

2.1 Bipartite drug--target networks
-----------------------------------

Drug Targetor v1.21 builds phenotype-dependent bipartite drug--gene networks using HTML 5 canvas and JavaScript ([Supplementary Fig. S1](#sup1){ref-type="supplementary-material"}). A bipartite network consists in two sets of disjoint and independent sets of nodes A and B. Edges connect nodes in A to nodes in B. In Drug Targetor networks, A = drugs and B = genes. Drugs and genes are connected by type of drug--gene or drug--target interaction ([Table 1](#bty982-T1){ref-type="table"}). Genes and drugs are ordered by genetic scores derived from GWAS. The web platform allows to choose the phenotype and tissue of interest, the drug ensemble to be used and the type of drug--target or drug--gene interaction. A total of 530 phenotypes are available in the interface as of October 2018. The drugs are subdivided into categories defined by the Anatomical Therapeutic Chemical Classification System (ATC, <https://www.whocc.no/atc_ddd_index>). Drug Targetor uses its own database of genetic scores for drugs and genes; users can choose to visualize the network for the top drugs, or a network corresponding to a specific ATC drug class.

###### 

Graphical elements of Drug Targetor networks

  Graphical element               Description
  ------------------------------- -------------------------------------------------------
  Blue connector                  Agonist, positive modulator
  Orange connector                Antagonist, negative modulator
  Brown connector                 Partial agonist
  Purple connector                Modulator
  Black connector                 Interaction but unknown mechanism of action
  Red connector                   Decreases gene expression
  Green connector                 Increases gene expression
  Grey connector                  Unknown effect on gene expression
  Left-hand table (drug table)    Drugs ordered by genetic score for a given phenotype
  Right-hand table (gene table)   Genes ordered by genetic score for a given phenotype
  Red/green cells (gene table)    Negative/positive tissue-dependent association result

2.2 Phenotype-dependent drug and gene scores
--------------------------------------------

Drugs and genes are ordered by GWAS-derived scores, which can be used as filters in the network construction. The drug score is the −log~10~(*P*-value) of the drug/phenotype association test, computed using MAGMA pathway analysis ([@bty982-B2]) after mapping each drug to its interacting genes. Gene scores, on the other hand, are a combination of two gene-wise tests (cf. [Supplementary Text S3](#sup1){ref-type="supplementary-material"} for details): MAGMA gene-wise association test and S-PrediXcan ([@bty982-B1]) tissue--gene association test, which uses eQTL data ([Supplementary Text S4](#sup1){ref-type="supplementary-material"}). The gene scores range from 1 to 7; genes with the highest score (7) are significant in both S-PrediXcan and MAGMA. Drug Targetor reports all S-PrediXcan *z*-scores; positive or negative *z*-scores correspond to up- or down-regulation in the tissue of interest.

2.3 Drug--target and drug--gene connections
-------------------------------------------

Different types of interactions can be selected in Drug Targetor and are used to connect drugs and targets: drug--gene interactions (how a drug influences gene expression), and drug--target interactions (how a drug interacts with a protein target). Drug--target interactions are further divided into drug mechanism of action (antagonist, agonist, modulator), and data measuring binding of a compound to a target ([Supplementary Text S1](#sup1){ref-type="supplementary-material"}). Different colours are attributed to the connections depending on interaction type (cf. [Table 1](#bty982-T1){ref-type="table"}). The different data sources and their references are reported in [Supplementary Table S1](#sup1){ref-type="supplementary-material"}.

3 Example
=========

We present an example of a Drug Targetor network based on a type 2 diabetes GWAS ([@bty982-B6]) in [Figure 1](#bty982-F1){ref-type="fig"}.

![Drug Targetor network representing top drugs and their targets with drug and gene scores derived from a type 2 diabetes genome-wide association study by [@bty982-B6]. Drug and gene scores were computed using MAGMA. Tissue-wise gene associations (*z*-scores) in the gene table were computed using S-PrediXcan](bty982f1){#bty982-F1}

Drugs with highest score are represented with their top targets (for gene filtering options, cf. [Supplementary Text S5](#sup1){ref-type="supplementary-material"}). Top-ranked drugs include already known diabetes drugs agonists of the glitazone receptor (PPARG gene), but also melatonin receptor 1B agonists. A recent study showed an improvement of sleep quality in type 2 diabetes patients with insomnia treated with ramelteon ([@bty982-B7]); evidence also points towards a link between melatonin and glucose homeostasis ([@bty982-B4]). Drug Targetor suggestions are supported by literature, indicating that such networks could be suggestive of repurposing opportunities.
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Click here for additional data file.
